ClinicalTrials.gg
Status unknownNCT04593316EXPLO-CCEUpdated Mar 9, 2021

Study of Risk Factors for the Occurrence and Severity of Exertional Heatstroke in the Military Environment

An observational study in Heat Stroke, sponsored by Direction Centrale du Service de Santé des Armées. Status unknown at 3 sites in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-09.

Sponsored by Direction Centrale du Service de Santé des Armées · Observational

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Although the circumstances of onset and management of exertional heatstroke have been identified for several years, its pathophysiology remains imperfectly understood. Exertional heatstroke is the result of both extrinsic (i.e. environmental) and intrinsic (i.e. individual) contributing factors.

Extrinsic factors are well known (high ambient temperature and hygrometry, poorly "breathable" clothing, intense and prolonged physical effort) but some of them may be observed in milder conditions. In the French Armed Forces, 25% of the exertional heatstrokes that have been reported between 2005 and 2011 occurred below 17°C.

Intrinsic factors, on the other hand, are numerous and less consensual, partly because of the imperfect knowledge of exertional heatstroke physiopathology. Potential factors include a thermoregulatory defect (inability to maintain a temperature plateau during an effort) and several genetic mutations may also contribute to explain a propensity to present an exertional heatstroke. While exertional heatstroke is clearly not a monogenic pathology, the association of several polymorphisms could contribute to this vulnerability. Among the genes that have been explored, mutations in ryanodine receptor type 1 (RyR 1), calsequestrin-1 or angiotensin-1 converting enzyme (ACE) appear to be potential candidates. However, it is very likely that other polymorphisms may be involved, such as: genes involved in sports performance and exercise rhabdomyolysis, in the inflammatory cascade, permeability of the digestive epithelial barrier, adenosine receptors and susceptibility to anxiety.

Finally, motivation is a mixed factor often claimed to be involved in exertional heatstroke but has never been quantified and needs to be objectified.

To date, none of these hypotheses has been clearly assessed by comparing patients who experienced exertional heatstroke to healthy subjects.

02

Conditions studied

  • Heat Stroke

Browse trials for

03

In context

Heat Stroke

21 studies on the registry are indexed under Heat Stroke; 10 are open to participants now.

Browse Heat Stroke studies →

Lead sponsor

Direction Centrale du Service de Santé des Armées is the lead sponsor of 95 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be composed of patients who are experiencing or who have experienced exertional heatstroke (heatstroke group) and people who have not (control group).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active military
  • Between 18 and 45 years old
  • Ability to the walk/run test

Exclusion criteria

Exclusion Criteria:

  • Ongoing drug treatment (for the control group only),
  • greater than or equal to 30,
  • to the ingestion of a core temperature capsule
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Exertional heatstroke group

    Patients presenting or having presented exertional heatstroke.

    Other: Saliva collection · Behavioral: Questionnaires · Other: Ingestible core temperature capsule intake · Other: Physical exercise · Other: Heart rate monitoring · Other: Core temperature monitoring

  • Control group

    Healthy people who never experienced exertional heatstroke.

    Other: Saliva collection · Behavioral: Questionnaires · Other: Ingestible core temperature capsule intake · Other: Physical exercise · Other: Heart rate monitoring · Other: Core temperature monitoring

Interventions

  • OtherSaliva collection

    A saliva sample will be collected before physical exercise.

  • BehavioralQuestionnaires

    The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.

  • OtherIngestible core temperature capsule intake

    The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.

  • OtherPhysical exercise

    The participant will perform a walk/run test.

  • OtherHeart rate monitoring

    Heart rate will be monitored during physical exercise thanks to a chest belt.

  • OtherCore temperature monitoring

    Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.

06

What researchers measure

Primary outcomes

  1. Difference of the frequency of CYP24A1 gene polymorphisms between the heatstroke group and the control group

    The frequency of CYP24A1 gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  2. Difference of the frequency of DRD2 gene polymorphisms between the heatstroke group and the control group

    The frequency of DRD2 gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  3. Difference of the frequency of BDNF gene polymorphisms between the heatstroke group and the control group

    The frequency of BDNF gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  4. Difference of the frequency of COMT gene polymorphisms between the heatstroke group and the control group

    The frequency of COMT gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  5. Difference of the frequency of FAAH gene polymorphisms between the heatstroke group and the control group

    The frequency of FAAH gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  6. Difference of the frequency of TPH2 gene polymorphisms between the heatstroke group and the control group

    The frequency of TPH2 gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  7. Difference of the frequency of GRIN2B gene polymorphisms between the heatstroke group and the control group

    The frequency of GRIN2B gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  8. Difference of the frequency of PER3 gene polymorphisms between the heatstroke group and the control group

    The frequency of PER3 gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  9. Difference of the frequency of TNF-a gene polymorphisms between the heatstroke group and the control group

    The frequency of TNF-a gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  10. Difference of the frequency of IL-6 gene polymorphisms between the heatstroke group and the control group

    The frequency of IL-6 gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  11. Difference of the frequency of IL1B gene polymorphisms between the heatstroke group and the control group

    The frequency of IL1B gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  12. Difference of the frequency of HSPA1B gene polymorphisms between the heatstroke group and the control group

    The frequency of HSPA1B gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

  13. Difference of the frequency of TLR4 gene polymorphisms between the heatstroke group and the control group

    The frequency of TLR4 gene polymorphisms will calculated in each group by dividing the number of participants who present the polymorphism by the total number of participants in the group.

    Time frame: At enrollment (day 1)

07

Study locations

1 of 3 sites recruiting
  • Institut de Recherche Biomédicale des Armées
    Brétigny-sur-Orge, 91223, France
    Not yet recruiting
  • Hôpital d'Instruction des Armées Laveran
    Marseille, 13384, France
    Recruiting
  • Ecole du Val-de-Grâce
    Paris, 75005, France
    Not yet recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04593316
Lead sponsor
Direction Centrale du Service de Santé des Armées
Responsible party
Sponsor
First posted
Oct 20, 2020
Start date
Nov 2, 2020
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
Mar 9, 2021

Study contacts

Arnaud-Xavier JOUVION, MD
Contact
arnaud-xavier.jouvion@intradef.gouv.fr
491617679 ext. +33
Keyne CHARLOT
Contact
keyne.charlot@intradef.gouv.fr
178651303 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion